Search Results

You are looking at 41 - 50 of 451 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride

analysis included adult patients diagnosed with mNSCLC who initiated nab-paclitaxel, sb-paclitaxel, or PD-L1 based 1L therapy from 1/1/2011 to 12/31/2017. Patients were continuously enrolled (CE) with medical and pharmacy benefits ≥6 months prior to mNSCLC

Full access

Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson

Background : Pembrolizumab+chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin) was recently granted FDA and EMA approval for first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer

Full access

Mary Cianfrocca and William J. Gradishar

cancer: phase III trial results . J Clin Oncol 2002 ; 20 : 2812 – 2823 . 4. O'Shaughnessy J Nag S Calderillo-Ruiz G . Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pretreated metastatic

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced-Stage or Recurrent Endometrioid Endometrial

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced-Stage or Recurrent Endometrioid Endometrial

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced or Recurrent Endometrioid Endometrial

Full access

Harold J. Burstein

regimens dramatically. In fact, you only need 1: AC (doxorubicin/cyclophosphamide) followed by paclitaxel. Here is the following evidence. The Oxford overview, based on treatment of over 100,000 women in adjuvant trials, suggests that all women who need

Full access

Augustine Lau, Jessy Delaisla, Jeff Dang, Sang Chau, and Andrew Hertler

control group. For those with advanced squamous NSCLC, the addition of pembrolizumab to paclitaxel/nab-paclitaxel with carboplatin provided a 6.4 months PFS advantage versus 4.8 months in the control group. Methods: The sample was obtained from a

Full access

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in

Full access

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced